Immunic Completes Phase 3 ENSURE Trials Enrollment for MS

Immunic, a biotechnology firm focusing on autoimmune diseases, announced the completion of patient enrollment for its Phase 3 ENSURE trials. These trials are evaluating vidofludimus calcium in patients with relapsing multiple sclerosis (MS). The ENSURE program involves two multicenter, randomized, double-blind trials, ENSURE-1 and ENSURE-2, involving over 2,200 patients across 15 countries.

Top-line data from these trials is anticipated by the end of 2026. Concurrently, new data from the Phase 2 CALLIPER trial in progressive MS supports previously positive outcomes. Vidofludimus calcium demonstrated significant reductions in disability progression, underscoring its neuroprotective potential. The company is hopeful that successful results could lead to regulatory approval and commercialization, offering a novel treatment for MS.